Professional
Added to YB: 2025-12-01
Pitch date: 2025-11-26
ILA.AX [neutral]
Island Pharmaceuticals Limited
-16.96%
current return
Author Info
Research as a Service is Australia’s leading independent investment research house sharing institutional-quality, issuer-sponsored research. Sign up for the newsletter.
Company Info
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America.
Market Cap
AUD 140.0M
Pitch Price
AUD 0.56
Price Target
1.14 (+151%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-24.32
EV/Sales
1.1K
Sector
Pharmaceuticals
Category
special_situation
Island Pharmaceuticals (ASX:ILA) - De-risking the commercial path
ILA.AX (update): Antiviral therapeutics targeting infectious diseases. Hired DC lobbying firm Todd Strategy Group & joined Medical Countermeasures Coalition to boost US gov't sales of Galidesivir for Marburg ahead of FDA clearance. Key risk mitigation as efficacy strong but being overlooked main commercial risk. rNPV price target $1.14/share.
Read full article (3 min)